Celltrion

Celltrion's reported carbon emissions

Celltrion, a pharmaceutical preparation manufacturer headquartered in South Korea (KR), is actively addressing its climate impact with defined emission reduction targets. For the most recent reporting year, 2024, Celltrion reported total absolute emissions of approximately 121,610,000 kg CO2e. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 27,146,000 kg CO2e, Scope 2 emissions were approximately 52,028,000 kg CO2e, and Scope 3 emissions totalled about 42,426,000 kg CO2e. In 2023, total absolute emissions were approximately 95,553,000 kg CO2e, with Scope 1 at about 22,457,000 kg CO2e, Scope 2 at approximately 42,260,000 kg CO2e, and Scope 3 at around 28,798,000 kg CO2e. Celltrion has established ambitious climate commitments. The company aims to achieve carbon neutrality by 2050. Furthermore, they have set a near-term goal to reduce Greenhouse Gas (GHG) emissions by 50% by 2030, using 2020 as the baseline year for this target. In parallel, Celltrion has announced a Net Zero commitment to reduce GHG emissions across its domestic operations. This commitment targets a reduction of Scope 1 and Scope 2 emissions by 42% by 2030 and achieving 100% reduction by 2045, with 2022 as the base year.